Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections

Clinical Pharmacology: Advances and Applications

Volumn 8, Issue , 2016, Pages 15-18

  Matsumoto, Kazuaki ^a   Watanabe, Erika ^a   Kanazawa, Naoko ^a   Fukamizu, Tomohide ^a   Shigemi, Akari ^a   Yokoyama, Yuta ^a,b   Ikawa, Kazuro ^b   Morikawa, Norifumi ^b   Takeda, Yasuo ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

AUC MIC; MRSA; PK PD; Teicoplanin

Indexed keywords

TEICOPLANIN;

ADULT; AGAR DILUTION; AGED; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

EID: 84962439717     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S96143     Document Type: Article

References (15)

1. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002; 19: 349-353.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26: 1-10.
3. Wilson AP, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents. 1994; 4(Suppl 1): 1-30.
4. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008; 14: 116-123.
5. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003; 17: 479-501.
6. Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013; 19: 365-380.
7. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
9. Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006; 54: 1-6.
10. Wikler MA, Hindler JF, Cockerill FR, et al. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard. 8th ed. Clinical and Laboratory Standards Institute; Wayne, PA, USA, 2009. Document M7-A8.
11. Matsumoto K, Kanazawa N, Ikawa K, et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J Infect Chemother. 2010; 16: 193-199.
12. Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother. 2012; 18: 10-16.
13. Kanazawa N, Matsumoto K, Ikawa K, et al. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J Infect Chemother. 2011; 17: 297-300.
14. Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int J Clin Pharmacol Ther. 2013; 51: 357-366.
15. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002; 50: 425-428.